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In the 15 years since the discovery of CD25
+
regulatory T cells (Tregs),1 the potential for
these cells to be exploited in the clinic has been
much touted, especially since the explosion
of research in the post-Foxp3 era. Hypothetical
treatments have been proposed to boost Tregs
in order to promote tolerance in the auto-
immune or transplantation contexts, and to
deplete Tregs in order to promote immunity
against cancers or persistent infections.
Whether Tregs would live up to the expecta-
tion has remained an open question, with
mixed results in preliminary trials. A forth-
coming paper by Di Ianni et al.2 suggests that
Tregs are indeed fulfilling expectations by
making the transition from bench to bedside.
The study of Di Ianni et al.2 used the
important clinical context of haploidentical
hematopoietic cell transplantation (HCT).
HCT is a potentially curative option for
many patients with hematological malignan-
cies.3 The ideal donor for HCT is a human
leukocyte antigen-identical donor, but often
only a donor sharing one human leukocyte
antigen-haplotype is available, resulting in
haploidentical HCT. Haploidentical HCT is
a classic example of a clinical situation, in
which the delicate balance between immu-
nity and tolerance has yet to be reached.
If T cells are included in the donor graft,
graft-versus-host disease (GVHD) results, a
life-threatening complication consisting of
the destruction of recipient organs by donor
T cells. By contrast, if T cells are depleted
prior to transplantation, GVHD is avoided,
but the risks of severe infections and tumor
relapse are dramatically increased because of
poor immune reconstitution.4
Until now the common decision was to err
on the side of infectious risk, by positively
selecting CD34+ hematopoietic stem progeni-
tor cells in the near-absence of T cells. There
have been several attempts to mitigate the
resulting 25% chance of infectious death,
such as through infusing cytotoxic T-cell
clones specific for the pathogens commonly
responsible for post-HCT infections, such as
cytomegalovirus and aspergillosis.5 As these
treatments are technically challenging and
do not provide a broad protection against
infection, there is a strong need to develop
a therapeutic strategy, which incorporates
T-cell infusion while preventing GVHD. The
concept of Treg infusion to prevent donor
T-cell-driven GVHD has been around since
the advent of suppressor T cells in the 1970s.6
The principle of Treg-mediated suppression
of GVHD was demonstrated in mice, where
the co-infusion of CD25+ Tregs and conven-
tional T cells resulted in a reconstituted
immune system without the advent of
GVHD,7,8 while still preserving graft-versus-
tumor activity.9
In the forthcoming paper published in
Blood, Di Ianni et al.2 adapted the mouse
model of Treg cell therapy to haploidentical
HCT patients. The trial was based on 28
high-risk adult patients suffering from
advanced hematological malignancies.2
Patients received a stringent myeloablative
conditioning regimen (Figure 1), followed
by the infusion of freshly isolated donor
CD25+ Tregs. Following this pre-condition-
ing, patients were transplanted with CD34+
hematopoietic stem cells, to reconstitute the
bone marrow, and conventional T cells to
reconstitute the immune system. As demon-
strated previously with conventional T-cell
infusion, immune reconstitution was fast,
with CD4 and CD8 donor T-cell counts
reaching the healthy range within 2–3 months
and pathogen-specific clones expanding
to counter infection. Most remarkably, of
the 28 patients only 2 developed acute
GVHD (X grade II) and none developed
chronic GVHD, despite no immunosuppres-
sion being used.2 It is notable that this effect
of Treg cell therapy in preventing GVHD is













Figure 1 Treg cell therapy schedule of the Di Ianni et al.2 study. Patients were conditioned through
a regimen of 8Gy total body irradiation, 200mgm2 fludarabine total dose, 8mgkg1 thiotepa total
dose, and 70mgkg1 cyclophosphamide total dose. On day 4, patients were infused with fresh Tregs
isolated through leukapheresis (2106 Tregs kg1). On day 0, patients were infused with CD34+ stem
cells (mean dose: 9106 cells kg1) and conventional T cells (0.5 to 4106 cells kg1).
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much stronger than that observed in previous
clinical trials utilizing ex vivo expanded
Tregs,10 suggesting that critical functions or
specificities are lost during the expansion
process. While overall mortality from infec-
tion in the Di Ianni study was still high, the
ability of Tregs to prevent GVHD after con-
ventional T-cell infusion is very promising for
future therapeutics.
The implications of this study for haploi-
dentical HCT are clear—for clinicians dealing
with GVHD, Treg-cell therapy is a viable
option. By manipulating the transplant sche-
dule to involve Tregs and conventional T-cell
transfer, Di Ianni et al.2 managed to stabilize
the immunological balance toward both bet-
ter control of tolerance (low GVHD) and
prompt immune reconstitution. More
broadly, however, this study shows that the
use of Tregs in a clinical setting is not just a
pipe dream, and that the fantastical proposals
for the manipulation of Tregs in everything
from autoimmunity to cancer may just end
up being feasible.
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